Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring
1 other identifier
interventional
32
1 country
1
Brief Summary
Noninvasively monitoring insulin is crucial for advancing precision nutrition and promoting healthy living by enabling a deeper understanding of individual metabolic responses to dietary intake. Insulin is a key regulator of blood sugar and energy metabolism, and its dysregulation is linked to conditions such as diabetes, obesity, and metabolic syndrome. By noninvasively tracking insulin levels, individuals can gain real-time insights into how their body processes different foods, allowing for the personalization of diets to optimize metabolic health, manage weight, and reduce disease risk. This approach also empowers proactive lifestyle adjustments to maintain insulin sensitivity, improve glycemic control, and enhance overall well-being. Decentralized insulin quantification in biofluids, including saliva and serum, based on lateral flow assay or electrochemical sensor has been reported. However, these approaches have poor sensitivity and fail to quantify insulin with a high temporal resolution.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 11, 2025
CompletedFirst Submitted
Initial submission to the registry
November 19, 2025
CompletedFirst Posted
Study publicly available on registry
November 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
November 28, 2025
November 1, 2025
1.2 years
November 19, 2025
November 19, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Quantification of protein biomarkers
Time-varying plasma insulin concentrations and correlation between sweat and dermal interstitial fluid.
up to 9 hours, 1 day
Study Arms (1)
Standardized liquid meal drink
EXPERIMENTALWe will provide a standardized drink consisting of whey, maltodextrin and sunflower oil, flavored using vanilla sugar-free instant pudding.
Interventions
We will use Whey powder (60g) as protein, Maltodextrin (Polycose; 170g) as carbohydrate, and Sunflower Oil (48g) as the fat source. The meal is mixed and flavored using vanilla sugar-free instant pudding.
Eligibility Criteria
You may qualify if:
- Age
- years old
- years old
- BMI between 22 and 35 kg/m2
- Ability to walk, sit down, and stand up (independently or with a walking assistance device)
- Willingness to lay supine in bed for up to 9 hours
- Willingness and ability to comply with the protocol
You may not qualify if:
- Known allergy to any of the components of the meal or agents used for the application of the devices
- Sunflower oil
- Maltodextrin
- Whey protein
- Pilocarpine solutions
- Established diagnosis and active treatment of chronic disease: insulin-dependent diabetes, active malignancy, heart failure, kidney disease, liver disease, HIV/AIDS, asthma (moderate to severe), Hep (A, B, or C)
- History of untreated metabolic disease including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Active dependence on alcohol or drugs
- Use of a short course of oral corticosteroids within 4 weeks preceding study day
- Current use of long-term oral corticosteroids
- Presence of fever within the last 3 days
- Planned elective surgery requiring 2 or more days of hospitalization during the entire study
- (Possible) pregnancy (confirmed via urine pregnancy test for females 18-30 years)
- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Texas A&M University
College Station, Texas, 77843, United States
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 19, 2025
First Posted
November 28, 2025
Study Start
September 11, 2025
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
November 28, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share